

STANDARD TREATMENT WORKFLOW (STW)

Sickle Cell Disease

Tulika Seth¹, Dipti Jain², Manisha Madkaikar³, N S Chatterjee⁴, P K Patra⁵, Roshan Colah⁶

¹All India Institute of Medical Science, New Delhi; ²Govt Medical College, Nagpur; ³Indian Council of Medical Research-National Institute of Immunohaematology Mumbai; ⁴Indian Council of Medical Research, New Delhi; ⁵Chandulal Chandrakar Memorial Government Medical College; ⁶Indian Council of Medical Research-National Institute of Immunohaematology Mumbai

CORRESPONDING AUTHOR

Dr Tulika Seth, Department of Haemolytic Anaemia, All India Institute of Medical Science, New Delhi
Email: drtulikaseth@gmail.com

CITATION

Seth T, Jain D, Madkaikar M, Chatterjee NS, Patra PK, Colah R. Sickle Cell Disease. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S49-S50.

DOI: <https://doi.org/10.56450/JEFI.2024.v2i1Suppl.025>

This work is licensed under a Creative Commons Attribution 4.0 International License.

©The Author(s). 2024 Open Access

DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.

eeoz/ampc






Department of Health Research
Ministry of Health and Family Welfare, Government of India




icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1950

Standard Treatment Workflow (STW) SICKLE CELL DISEASE ICD-10-D57






Standard Treatment Workflow (STW)
SICKLE CELL DISEASE
ICD-10-D57



THIS FAMILY TREE SHOWS THROUGH MENDELIAN TRANSMISSION - THE RISK OF HAVING AFFECTED CHILDREN ACROSS GENERATION IN PARENTS WITH SCD - HETEROZYGOUS AND HOMOZYGOUS.



CLINICAL MANIFESTATIONS OF SCD	Target group to be screened	Tests / remarks
<ul style="list-style-type: none"> Common presentations - Pain, anemia, icterus, increased risk of infection Acute morbidity/ events - Splenic sequestration, fatigue, acute chest syndrome, priapism Long term complications - End organ damage, hepatopathy, chronic kidney disease, hypersplenism, avascular necrosis of femur, osteomyelitis, pulmonary hypertension, cholelithiasis, functional disability, retinopathy, foot ulcers- refer to a higher center for adequate management 	Antenatal Mothers or pre-pregnancy planning	<ul style="list-style-type: none"> CBC all women in first trimester In endemic pockets/ high risk population: solubility test/ POC tests for sickle cell Or HPLC and electrophoresis, if available If mother is a sickle cell carrier/ disease, then testing of father is mandatory. Ideally by HPLC, if not available refer to higher center If father tests positive, counselling and pre-natal testing should be performed (at centers with necessary facilities) to prevent risk of birth of affected newborn
	Newborn	<ul style="list-style-type: none"> POC tests to initiate penicillin prophylaxis in baby and enrolling vaccination program HPLC and electrophoresis, if available or at later date
	Population screening/ patient of any age	<ul style="list-style-type: none"> In endemic pockets/ high risk population: solubility test/ POC tests for sickle cell

GENERAL PRINCIPALS OF MANAGEMENT	PROPHYLAXIS FOR ALL SCD PATIENTS						
<ul style="list-style-type: none"> Carriers are usually asymptomatic and needs no treatment The goal of management is to improve quality of life and life expectancy of the affected individuals Episodes of fever have to be dealt with early and aggressively Early and aggressive management of pain should be advocated, since pain may be indicative of microvascular organ damage. Pain management using paracetamol, diclofenac or tramadol. For severe pain, refer to higher centre Malaria in SCD patients will be present with same frequency as endemic prevalence Evaluate for anaemia. Iron supplements for anaemia to be used cautiously (low dose - not more than 3 months). Other nutritional causes (Vit B12, and Folic acid deficiency) and infectious causes (worm infestations) to be evaluated Prophylaxis for infections- penicillin, immunizations and folic acid supplement, disease modifying agents like hydroxyurea (HU) and blood transfusions have specific indications Acute morbidity events occur over the lifetime and require management, regular monitoring may help to reduce severity of complications Only curative therapy is hematopoietic stem cell transplantation. This is recommended and beneficial in a small subset of patients not responding to HU or newer disease modifying agents 	<table border="1"> <tr> <td>New born HbSS till 5 years of age</td> <td>Penicillin prophylaxis- 65mg BD, less than 12 months 125 mg BD till 2 years, then 250mg BD till 5 years lifelong if post splenectomy</td> </tr> <tr> <td>To prevent megaloblastic crises</td> <td>Folic acid- less than 1 year of age, 2.5 mg daily 1 year of age, 5 mg daily</td> </tr> <tr> <td>Common recommended vaccinations</td> <td>Pneumococcal Vaccine H-influenza vaccine Typhoid Vaccine Influenza vaccine COVID 19 vaccine</td> </tr> </table>	New born HbSS till 5 years of age	Penicillin prophylaxis- 65mg BD, less than 12 months 125 mg BD till 2 years, then 250mg BD till 5 years lifelong if post splenectomy	To prevent megaloblastic crises	Folic acid- less than 1 year of age, 2.5 mg daily 1 year of age, 5 mg daily	Common recommended vaccinations	Pneumococcal Vaccine H-influenza vaccine Typhoid Vaccine Influenza vaccine COVID 19 vaccine
New born HbSS till 5 years of age	Penicillin prophylaxis- 65mg BD, less than 12 months 125 mg BD till 2 years, then 250mg BD till 5 years lifelong if post splenectomy						
To prevent megaloblastic crises	Folic acid- less than 1 year of age, 2.5 mg daily 1 year of age, 5 mg daily						
Common recommended vaccinations	Pneumococcal Vaccine H-influenza vaccine Typhoid Vaccine Influenza vaccine COVID 19 vaccine						

HOW TO PRESCRIBE HYDROXYUREA	Red Flag for hospitalization or referral to higher centre	EDUCATION AND GENETIC COUNSELLING								
<table border="1"> <thead> <tr> <th>Indications for HU</th> <th>Baseline Investigations</th> <th>Dosing</th> <th>Toxicity</th> </tr> </thead> <tbody> <tr> <td> <ul style="list-style-type: none"> Above 2 years of Age All children more than 9 months of age may be offered </td> <td> <ul style="list-style-type: none"> Complete physical Examination CBC Liver function test Renal function Pregnancy test for relevant population </td> <td> <ul style="list-style-type: none"> Infants and Children: 10-15 mg/kg/day Adolescents: 15mg/kg/day Dose escalation by 5 mg/kg; 2-3 months only in definite indications CBC monitoring 1-3 months when starting the medicine or if dose change </td> <td> <ul style="list-style-type: none"> Common dose dependent toxicity: anaemia, nausea, diarrhoea, gastritis Nail/ skin hyperpigmentation Long term toxicity: Mucositis or leg ulcers </td> </tr> </tbody> </table>	Indications for HU	Baseline Investigations	Dosing	Toxicity	<ul style="list-style-type: none"> Above 2 years of Age All children more than 9 months of age may be offered 	<ul style="list-style-type: none"> Complete physical Examination CBC Liver function test Renal function Pregnancy test for relevant population 	<ul style="list-style-type: none"> Infants and Children: 10-15 mg/kg/day Adolescents: 15mg/kg/day Dose escalation by 5 mg/kg; 2-3 months only in definite indications CBC monitoring 1-3 months when starting the medicine or if dose change 	<ul style="list-style-type: none"> Common dose dependent toxicity: anaemia, nausea, diarrhoea, gastritis Nail/ skin hyperpigmentation Long term toxicity: Mucositis or leg ulcers 	<ul style="list-style-type: none"> Acute illness requiring immediate medical care, including emergencies Persistent Temperature $>38^{\circ}\text{C}$ Pain inadequately relieved by home measures Significant respiratory symptoms (cough, shortness of breath, chest pain) or hypoxia Abdominal pain, distention, acute enlargement of spleen Any neurological signs or symptoms Significant increase in pallor, fatigue, lethargy Significant vomiting and diarrhoea 	<ul style="list-style-type: none"> Medical disease counselling - Explain the clinical presentation, severity, consequences of the disease. Importance of early diagnosis by newborn screening and comprehensive care. Teach patients and parents -avoid infections, be adequately hydrated, balanced nutrition, avoid over exercise, avoid extreme temperatures, importance of penicillin prophylaxis, need for regular clinical follow up of patients Genetic counselling - Explain carrier state and risk of having an affected child. Document family history, consanguinity, draw a pedigree chart, explain the inheritance pattern and risk of recurrence Preconception care counselling - for at-risk couples by following recommended practices. Give options and referrals Pre and post test support to the family - while making decisions and eliminating irrational fears, stigmatization, maintaining confidentiality Cascade screening - Emphasize the need for screening of extended family members
Indications for HU	Baseline Investigations	Dosing	Toxicity							
<ul style="list-style-type: none"> Above 2 years of Age All children more than 9 months of age may be offered 	<ul style="list-style-type: none"> Complete physical Examination CBC Liver function test Renal function Pregnancy test for relevant population 	<ul style="list-style-type: none"> Infants and Children: 10-15 mg/kg/day Adolescents: 15mg/kg/day Dose escalation by 5 mg/kg; 2-3 months only in definite indications CBC monitoring 1-3 months when starting the medicine or if dose change 	<ul style="list-style-type: none"> Common dose dependent toxicity: anaemia, nausea, diarrhoea, gastritis Nail/ skin hyperpigmentation Long term toxicity: Mucositis or leg ulcers 							

EARLY AND AGGRESSIVE MANAGEMENT OF PAIN AND INFECTIONS WILL HELP IMPROVE LONG TERM OUTCOME

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (stw.icmr.org.in) for more information. ©Department of Health Research, Ministry of Health & Family Welfare, Government of India.